SEC Company Response from Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Jul 24, 2017
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: July 24, 2017 · CIK: 0001506251 · Accession: 0001477932-17-003507
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217956
Letter
RE:
ctxr_corresp.htm
July 24, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Citius Pharmaceuticals, Inc. (CIK: 0001506251) (the “Company”)
Registration Statement No. 333-217956 on Form S-1 (the “Registration Statement”)
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp., as representative of the underwriters of the offering, hereby joins the request of the Company that the effective date of the above-captioned Registration Statement be accelerated so as to permit it to become effective on Wednesday, July 26, 2017, at 5:00 p.m., EST, or as soon thereafter as practicable.
Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act, we, acting on behalf of the several underwriters, wish to advise you that, through July 24, 2017, we distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated July 24, 2017, as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
By:
AEGIS CAPITAL CORP.
By:
/s/ Thomas Higgins
Name:
Thomas Higgins
Title:
SVP
Show Raw Text
CORRESP 1 filename1.htm ctxr_corresp.htm July 24, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Citius Pharmaceuticals, Inc. (CIK: 0001506251) (the “Company”) Registration Statement No. 333-217956 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Aegis Capital Corp., as representative of the underwriters of the offering, hereby joins the request of the Company that the effective date of the above-captioned Registration Statement be accelerated so as to permit it to become effective on Wednesday, July 26, 2017, at 5:00 p.m., EST, or as soon thereafter as practicable. Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act, we, acting on behalf of the several underwriters, wish to advise you that, through July 24, 2017, we distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies, as well as “E-red” copies of the Preliminary Prospectus dated July 24, 2017, as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. By: AEGIS CAPITAL CORP. By: /s/ Thomas Higgins Name: Thomas Higgins Title: SVP